Arcutis Biotherapeutics Inc. held its 2025 Annual Meeting of Stockholders on June 12, 2025. During the meeting, stockholders voted on the election of three Class II directors, Bhaskar Chaudhuri, Ph.D., Sue-Jean Lin, and Howard G. Welgus, M.D., all of whom were elected. Additionally, the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. All proposals presented at the meeting were approved.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001787306-25-000096), on June 17, 2025, and is solely responsible for the information contained therein.